BT200 in Hereditary Bleeding Disorders

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

September 10, 2021

Study Completion Date

September 10, 2021

Conditions

Von Willebrand DiseasesHemophilia A

Interventions

DRUG

BT200

BT200 is a PEGylated synthetic RNA oligonucleotide

Trial Locations (1)

Medical University of Vienna, Vienna

All Listed Sponsors

lead

Medical University of Vienna

OTHER

NCT04677803 - BT200 in Hereditary Bleeding Disorders | Biotech Hunter | Biotech Hunter